AUSTIN, Texas, Oct. 18, 2011 /PRNewswire/ — A new patent covering tumor suppression technologies, including the company’s lead product candidate Oncoprex™, was recently awarded to The University of Texas System by the Japan Patent Office. Patent number 4813746 pertains to the discovery that chromosome 3p21.3 genes act as cancer suppressors. The family of tumor suppressors include TUSC2, also known as FUS1, the anti-cancer agent in Oncoprex therapy which is undergoing clinical evaluation for lung cancer patients in the U.S.